Cholesterol emboli syndrome medical therapy

Jump to navigation Jump to search

Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome medical therapy

CDC on Cholesterol emboli syndrome medical therapy

Cholesterol emboli syndrome medical therapy in the news

Blogs on Cholesterol emboli syndrome medical therapy

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Treatment of an episode of cholesterol emboli is generally symptomatic, i.e. it deals with the symptoms and complications but cannot reverse the phenomenon itself. In kidney failure resulting from cholesterol crystal emboli, statins have been shown to halve the risk of requiring hemodialysis.

  • No definitive therapy at this time; supportive care, fluids
  • The role of anticoagulation is not clear – some of advocated anticoagulation and others have warned against it.
  • Some have advocated lipid-lowering agents.
  • Unclear role for glucocorticoids, even when significant eosinophilia is present
    • Anecdotal case reports have reported improvement

References


Template:WikiDoc Sources